What about the 3 options presented in September 2020. Would this not supersede anything that came before it?

"Option 1, Resverlogix will now finalize its ongoing negotiations with Major Pharmaceutical companies to determine a suitable partner for co-developing apabetalone. Co-development discussions include the following: ▪ Resverlogix will receive a significant upfront payment H2, 2020. ▪ The Phase 3b clinical trial will be funded by the partnering company - $120 to $150 MM USD. ▪ Our new partner can supply their SGLT2 diabetes drug as the co-medication. Thus providing the pharma partner with valuable marketing material and the ability to launch a fixed-dose combination product with patent coverage until 2040. ▪ The deal will also include substantial milestone and royalty payments with an M&A right of first refusal option. 

• Option 2, Resverlogix can finance the Phase 3b trial internally through the sale of 50% of the future royalty stream currently owned by Zenith Capital. Funds would be used to finance BETonMACE2. 

• Option 3, Resverlogix can finance and launch the Phase 3b trial with internal insider investors."

Koo